Year: 2022

Michael Keidar – Plasma Medicine Using Cold Plasmas to Kill Cancer Cells Could plasma potentially provide a cure for some cancers? When a plasma at close to room temperature is applied directly to cancerous tissue, it can selectively kill cancer…

Hyperviscosity Syndrome | What Is The Cause? 😍🖼Animated Mnemonics (Picmonic): https://www.picmonic.com/viphookup/medicosis/ – With Picmonic, get your life back by studying less and remembering more. Medical and Nursing students say that Picmonic is the most comprehensive and effective way to bridge…

Top Multiple Myeloma Abstracts Presented at ASH 2021 IMF Chief Medical Officer Dr. Joseph Mikhael discusses the top Multiple Myeloma Abstracts presented at ASH 2021 _______________ Improving Lives | Finding the Cure In the United States, an estimated 32,270 new…

Pomalidomide in Multiple Myeloma Morie A. Gertz, MD; Rafael Fonseca, MD; Noopur Suresh Raje, MD; and Jatin J. Shah, MD, explain the role of the immunomodulatory drug, pomalidomide, in the management of multiple myeloma.

Relapsed Refractory Multiple Myeloma | Current Treatment Options | Options on the Horizon In the first portion, hosted by Nina Shah, MD, Professor of Clinical Medicine, Multiple Myeloma Translational Initiative, Division of Hematology-Oncology, University of California San Francisco, San Francisco,…

Everything to Know About Blood Cancer | Dr. Deepankar Bhattacharya | Medanta Blood cancer is defined as the cancer of blood-forming tissues, hindering the body’s ability to fight infection. A type of blood cancer, leukaemia, includes bone marrow as well….

Multiple Myeloma Treatment | Blood Disorder Treatment in India #multiplemyeloma #blooddisorder #bonemarrowtransplant Ms Ann visited from Lagos, Nigeria for Multiple Myeloma Treatment. She was struggling for a very long time with lot of pains and other medical issues. Medsurge India…

Challenges and future perspectives for minimal residual disease (MRD) in multiple myeloma Irene Ghobrial, MD from Dana-Farber Cancer Institute, Boston, MA, chairs a discussion on the detection of minimal residual disease (MRD) in multiple myeloma (MM) patients during the 2017…

MM & Plasma cell dyscrasia

Benefits of alnuctamab in the treatment of R/R multiple myeloma Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, outlines the advantages of the alnuctamab (formerly CC-93269), a novel BCMAxCD3…